This story has been updated to clarify details of Foundation Medicine's FoundationOne CDx.
CHICAGO – Although NantHealth won US Food and Drug Administration 510(k) clearance last week for its Omics Core whole-exome test for determining tumor mutational burden, the company cannot market it as a test that can predict whether cancer patients will respond to a specific immunotherapy.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
